Clinical Trial Update: Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating enzalutamide with mifepristone in metastatic hormone-resistant prostate cancer completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Hormone-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• Mifepristone (mifepristone)

Snippet

Sponsor: University of Chicago | Conditions: Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-07-13